Ranitidin and Nosocomial Infection in Very Low Birth Weight Infants


Seyyed Abolfazl Afjeh 2 , * , Mohammad Kazem Sabzehei 3 , Abdollah Karimi 1 , Fatemeh Esmaili 2

2 Mahdieh Medical Center , Shahid Beheshti University of Medical Sciences, [email protected], IR Iran

3 Hamedan University of Medical Sciences, IR Iran

1 Pediatric Infections Research Center, Shahid Beheshti University of Medical Sciences, IR Iran

How to Cite: Afjeh S A, Sabzehei M K, Karimi A, Esmaili F. Ranitidin and Nosocomial Infection in Very Low Birth Weight Infants, Arch Pediatr Infect Dis. Online ahead of Print ; 1(2):65-70. doi: 10.5812/pedinfect.9051.


Archives of Pediatric Infectious Diseases: 1 (2); 65-70
Published Online: July 15, 2013
Article Type: Research Article
Received: November 8, 2012
Accepted: November 22, 2012


Background: Nosocomial infections increase mortality rate in neonates. Studies have attributed the use of H2 blockers as one of the various factors that increase the risk of nosocomial infections.

Objectives: To define the relationship between nosocomial infection and Ranitidine in very low birth weight (VLBW) infants admitted in the NICU of a tertiary care hospital.

Patients and Methods: All VLBW infants admitted during the study period of 3 years from April 2008 to March 2011 were included. All relevant pre-and peri-natal data including all administered medications was collected from the case notes and documented on a pre-designed questionnaire. Rate of nosocomial infection (NI) had been compared between patients who were administered Ranitidine and those who did not receive this medication.

Results: During the study period, 564 VLBW infants were admitted in the NICU; 157, (27.8%) contracted nosocomial infections, 130 (82.8%) developed pneumonia, 21, (13.4%) had sepsis with positive blood cultures and 6 infants (1.1%) developed necrotizing enterocolitis. Factors remaining independently significant for development of NI after adjustment were as follows: RDS (P = 0.001. OR = 3.29; 95%CI = 1.646.6); CLD (P < 0.001. OR = 3.83; 95%CI = 2.067.11); anemia (P = 0.005. OR = 1.96; 95% CI = 1.23-3.13); use of Ibuprofen (P = 0.03. OR = 1.99; 95%CI = 1.06-3.74), and treatment with Ranitidine (P = 0.009, OR = 1.92, 95%CI = 1.18-3.12).

Conclusions: Use of Ranitidine was associated with a significantly increased risk of nosocomial infections in VLBW infant.

Full Text

Full text is available in PDF

© 2013, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.